Related Experiment Videos
Psoriasis and the new biologic agents: interrupting a T-AP dance
Scott R A Walsh1, Neil H Shear
1Department of Medicine, Division of Dermatology, Sunnybrook and Women's College Health Sciences Centre, University of Toronto, Toronto, Ont.
Summary
Novel biologic agents effectively treat psoriasis by targeting specific steps in the T-cell and antigen-presenting cell (APC) interaction, known as the "T-AP dance." These targeted therapies offer a safer, more effective alternative for moderate to severe cases.
Area of Science:
- Immunodermatology
- Molecular immunology
- Pharmacology
Background:
- Psoriasis is a chronic immune-mediated skin condition.
- It involves sustained T-cell activation by skin-resident antigen-presenting cells (APCs).
- This interaction is conceptualized as a sequential "T-AP dance" critical for T-cell activation.
Purpose of the Study:
- To review novel biologic agents for psoriasis treatment.
- To elucidate their mechanisms of action targeting the T-AP interaction.
- To assess their efficacy and safety in moderate to severe psoriasis.
Main Methods:
- Review of engineered proteins including fusion proteins, monoclonal antibodies, and recombinant cytokines.
- Analysis of their specific molecular targets within the T-AP activation pathway.
- Evaluation of clinical data on efficacy and safety.
Main Results:
- Biologic agents demonstrate efficacy by modulating T-cell activation, costimulation, and proliferation.
- Mechanisms include immune deviation and specific cytokine blockade.
- These agents show potential for increased pathway selectivity.
Conclusions:
- Novel biologic agents represent a significant advancement in treating moderate to severe psoriasis.
- Their targeted mechanisms offer improved efficacy and safety profiles.
- These therapies provide a valuable alternative to existing treatments by precisely interfering with immune dysregulation.